MMadrigal Pharmaceuticals develops therapies for nonalcoholic steatohepatitis (NASH) and related liver diseases, focusing on patients with moderate to advanced fibrosis and compensated cirrhosis. Its first therapy has FDA accelerated approval and is in Phase 3 trials, with revenue from sales and potential partnerships. The exact mechanism of action isn’t detailed, but the product has demonstrated clinical benefit in trials and ongoing safety validation. The company differentiates itself by a focused NASH program with accelerated approval and continued Phase 3 development, plus possible licensing deals, aiming to bring approved treatments to patients.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
West Conshohocken, PA
Founded
2011
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$2.3B
Above
Industry Average
Funded Over
11 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
West Conshohocken, PA
Founded
2011
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs